CMK-389 Drug Asset Due Diligence Report 2026

This CMK-389 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether CMK-389 can convert its Monoclonal antibody profile and IL-18 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	CMK-389 (query alias: CMK-389)
Modality / target	Monoclonal antibody; IL-18; IL-18 inhibitors
Highest global status	Phase 2
Originator	Novartis Pharma AG
Active developers	Novartis AG

The MCP disease footprint includes Dermatitis, Atopic, Sarcoidosis, Pulmonary. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2071210115	Phase 1	Complete	32	Primary endpoint not disclosed in English source
NCT04836858	Phase 2	Completed	71	Primary endpoint not disclosed in English source
NCT04064242	Phase 2	Completed	62	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Phase 2; n=62; evaluation: Not stated in English source. Reported fields: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment(Mean) = -0.48 Percent predicted ; Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment(Mean) = 1.02 Percent predicted

A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2; n=71; evaluation: Not stated in English source. Reported fields: Number of Participants With Investigator Global Assessment (IGA) Response = 5 Pts ; Number of Participants With Investigator Global Assessment (IGA) Response = 2 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

CMK-389 addresses Dermatitis, Atopic, Sarcoidosis, Pulmonary. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 5 matched transaction record(s) under the scope “target-level comparable: IL-18.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-18 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-01-28	AB2 Bio and Nippon Shinyaku enter Tadekinig alfa licensing deal	Phase 3	US$6.0M upfront; US$680.0M milestones
2024-06-24	Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio	Phase 1	Financial terms not disclosed
2022-10-31	Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO